HAVCR2 and ovarian serous cystadenocarcinoma: HAVCR2 expression was remarkably increased in 21 tumor types: BRCA, CESC, COAD, ESCA, CHOL, HNSC, lymphoid neoplasm diffuse large B-cell lymphoma (DLBCL), GBM, KIRC, KIRP, acute myeloid leukemia (AML), brain lower-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), PAAD, ovarian serous cystadenocarcinoma (OV), THCA, testicular germ cell tumors (TGCT), UCEC, skin cutaneous melanoma (SKCM), STAD, and uterine carcinoma (UCS).